Sign In
Buy CPRX
$31.28
+0.0100 (+0.0320%)
At Close: Jun 03, 2026
Catalyst Pharmaceutical (CPRX) is a Top-Ranked Value Stock: Should You Buy?
10:41am, Monday, 15'th Sep 2025
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Value Stock
10:41am, Friday, 29'th Aug 2025
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences
08:03am, Thursday, 28'th Aug 2025
CORAL GABLES, Fla., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, dev
UPDATED- Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Lupin Pharmaceuticals
07:12pm, Tuesday, 26'th Aug 2025
As Part of the Settlement, Lupin Receives a License to Market Generic FIRDAPSE Beginning in February 2035 As Part of the Settlement, Lupin Receives a License to Market Generic FIRDAPSE Beginning in Fe
Catalyst Pharmaceuticals Settles Firdapse Patent Litigation With Lupin
12:21pm, Tuesday, 26'th Aug 2025
CPRX secures a key win as its Firdapse patent litigation settlement with Lupin shields U.S. sales from generic competition until 2035.
Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Lupin Pharmaceuticals
08:03am, Monday, 25'th Aug 2025
As Part of the Settlement, Lupin Receives a License to Market Generic FIRDAPSE Beginning in February 2035 As Part of the Settlement, Lupin Receives a License to Market Generic FIRDAPSE Beginning in Fe
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Growth Stock
10:46am, Friday, 15'th Aug 2025
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Catalyst Pharmaceutical (CPRX) is a Top Value Stock for the Long-Term
10:41am, Wednesday, 13'th Aug 2025
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Catalyst Pharmaceuticals, Inc. (CPRX) Q2 2025 Earnings Call Transcript
02:21pm, Thursday, 07'th Aug 2025
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX ) Q2 2025 Earnings Conference Call August 7, 2025 8:30 AM ET Company Participants Jeffrey Del Carmen - Executive VP & Chief Commercial Officer Michael W. Ka
Catalyst Pharmaceuticals Q2 Earnings Beat, Firdapse Revenues Rise Y/Y
11:10am, Thursday, 07'th Aug 2025
CPRX beats Q2 earnings and revenue estimates as Firdapse and Agamree drive strong top-line growth.
Catalyst (CPRX) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
08:01pm, Wednesday, 06'th Aug 2025
While the top- and bottom-line numbers for Catalyst (CPRX) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare t
Catalyst Pharmaceutical (CPRX) Q2 Earnings and Revenues Surpass Estimates
07:40pm, Wednesday, 06'th Aug 2025
Catalyst Pharmaceutical (CPRX) came out with quarterly earnings of $0.68 per share, beating the Zacks Consensus Estimate of $0.58 per share. This compares to earnings of $0.56 per share a year ago.
Catalyst Pharmaceuticals Reports Record Second Quarter and First Half 2025 Financial Results; Provides Business Update
04:13pm, Wednesday, 06'th Aug 2025
Achieved Record Q2 2025 Total Revenues of $146.6 Million, an Increase of 19.4% Yo Y, Marking Another Quarter of Consecutive Growth Reported Record First Half 2025 Total Revenues of $288.0 Million, an
CORAL GABLES, Fla., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, dev
Catalyst Pharmaceuticals Appoints Daniel Curran, MD, to its Board of Directors
08:03am, Monday, 04'th Aug 2025
CORAL GABLES, Fla., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX) today announced the appointment of Daniel Curran, MD, to its Board of Dire
